Literature DB >> 7661904

Why have new effective therapies for sepsis not been developed?

L A Eidelman1, C L Sprung.   

Abstract

Entities:  

Mesh:

Year:  1994        PMID: 7661904     DOI: 10.1097/00003246-199408000-00018

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  7 in total

Review 1.  Recognition, treatment and complications of meningococcal disease.

Authors:  F A Riordan; A P Thomson
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.022

Review 2.  New therapeutic approaches in sepsis: a critical review.

Authors:  L A Eidelman; R Pizov; C L Sprung
Journal:  Intensive Care Med       Date:  1995-11       Impact factor: 17.440

3.  A plea for caution in the performance of sepsis trials.

Authors:  C L Sprung; J Cohen; L A Eidelman
Journal:  Intensive Care Med       Date:  1995-05       Impact factor: 17.440

4.  The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*.

Authors:  Steven M Opal; R Phillip Dellinger; Jean-Louis Vincent; Henry Masur; Derek C Angus
Journal:  Crit Care Med       Date:  2014-07       Impact factor: 7.598

5.  Risk factors for sepsis and endocarditis and long-term survival following coronary artery bypass grafting.

Authors:  Ioannis K Toumpoulis; Constantine E Anagnostopoulos; Stavros K Toumpoulis; Joseph J De Rose; Daniel G Swistel
Journal:  World J Surg       Date:  2005-05       Impact factor: 3.352

Review 6.  Advances in sepsis therapy.

Authors:  Thomas Glück; Steven M Opal
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Rational use of computerized protocols in the intensive care unit.

Authors:  A H Morris
Journal:  Crit Care       Date:  2001-09-13       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.